Physician profile
Ginger Brown
NPI 1477571529
$1,647.32
in general payments reported to CMS, 2019-2025
17 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.22 · 2020: $360 · 2021: $195 · 2022: $521 · 2023: $151 · 2024: $129 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $512.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $351.49 | 2019-2023 | Cequa |
| Johnson & Johnson Vision Care, INC. | $220.78 | 2020-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $216.31 | 2022-2025 | Infuse, Vyzulta, Lotemax Sm |
| Glaukos Corporation | $163.39 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $135.99 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $85.39 | 2020-2022 | |
| Abbvie INC. | $72.12 | 2022-2023 | Vuity, Lumigan, Alphagan P |
| Alcon Vision LLC | $64.26 | 2020-2025 | Precision 1 |
| Harrow Eye, LLC | $62.71 | 2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $47.12 | 2025 | Xdemvy |
| Biotissue Holdings INC. | $42.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.96 | 2021-2022 | |
| Allergan, INC. | $36.53 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $34.13 | 2022 | |
| Oyster Point Pharma, INC. | $28.23 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $26.12 | 2024 | Oxervate |
| Astellas Pharma US INC | $21.54 | 2025 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginger Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.